Table 1.

Combined North American Risperidone Trial: BPRS Total Score Mean Change^a From Baseline by Treatment and Week and Time Course of Estimated Treatment Effects

Week	Placebo		Haloperidol		Risperidone 2 mg		Risperidone 6 mg		Risperidone 10 mg		Risperidone 16 mg
Changes from baseline
	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE	Mean	SE
Baseline	54.2	1.2	54.9	1.3	52.1	1.2	55.0	1.3	53.2	1.3	54.2	1.2
1	−1.5	1.1	−2.9	1.1	−3.3	1.1	−7.2	1.1	−3.1	1.1	−5.6	1.1
2	−2.0	1.4	−3.6	1.3	−4.3	1.3	−10.4	1.3	−5.4	1.3	−8.4	1.3
4	−0.4	1.5	−5.2	1.5	−4.8	1.5	−11.8	1.4	−5.9	1.5	−9.9	1.5
6	2.8	1.8	−5.5	1.7	−3.4	1.7	−13.0	1.6	−6.5	1.6	−9.6	1.6
8	3.1	2.0	−4.8	1.9	−3.4	1.8	−11.8	1.8	−7.3	1.8	−9.4	1.8
Differences from placebo
			Diff	%max	Diff	%max	Diff	%max	Diff	%max	Diff	%max
1			1.5	17.7	1.8	28.0	5.8	36.5	1.6	15.6	4.2	33.2
2			1.7	20.1	2.3	34.9	8.4	52.9	3.4	32.8	6.4	51.0
4			4.8	57.9	4.5	68.2	11.4	71.9	5.5	53.1	9.5	76.0
6			8.3	100.0	6.2	95.1	15.8	100.0	9.3	89.5	12.4	98.6
8			7.9	96.2	6.5	100.0	14.9	94.3	10.4	100.0	12.5	100.0

^aEstimated from mixed model for incomplete repeated measures: D_ikt = week_t + treatment_k + week_t × treatment_k + error. Observed means and SEs are presented for baseline BPRS total score